- Investopedia•9 hours ago
Roche filed suit to fend off competition from Amgen’s biosimilar for its bestselling drug Avastin.
- Motley Fool•11 hours ago
These drug kingpins are raking in the dough, which could lead to handsome returns for investors.
- Reuters•3 days ago
Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||30.29 - 30.55|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.75|
|Dividend & Yield||1.02 (3.34%)|
|1y Target Est||N/A|